Boston-based Verve Therapeuticss’ study for its one-time drug treatment found patients treated with possible therapeutic doses had between a 39% and 55% reduction in LDL cholesterol.
A second drug, lepodisiran, reduced the harmful risk factor lipoprotein(a) by 94%. The reductions lasted nearly a year, according to the phase 1 study published in the Journal of the American Medical Association. Lp(a) is a form of cholesterol with characteristics in common with LDL cholesterol, according to a Nov. 12 American Heart Association news release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
